Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Earnings for Avidity Biosciences, Inc. (RNA)
Earnings in 2023 (TTM): $-212,220,000
According to Avidity Biosciences, Inc.'s latest financial reports the company's current earnings (TTM) are $-212,220,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Avidity Biosciences, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-212,220,000 | $-212,220,000 |
| 2022 | $-173,995,000 | $-169,077,000 |
| 2021 | $-118,009,000 | $-117,370,000 |
| 2020 | $-44,355,000 | $-43,982,000 |
| 2019 | $-24,734,000 | $-32,121,000 |
| 2018 | $-11,216,000 | $-11,934,000 |